What do systematic reviews say?

Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 691 participants
  Low

Sunitinib vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 544 participants
  Moderate

Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 401 participants
  Low

Sunitinib vs atezolizumab (targeted therapy versus immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 157 participants
  Low

Temsirolimus + IFN‐α vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 394 participants
  Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 460 participants
  Moderate

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Exercise vs control

• Exercise for women receiving adjuvant therapy for breast cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Low

Sunitinib vs avelumab + axitinib (targeted agent versus immunotherapy + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Everolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy)

The review found no eligible studies for this question.

• Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

CBT vs usual care

Cognitive‐behavioural therapy probably leads to higher health‐related quality of life Investigators measured health‐related… compared with usual care (moderate certainty).

• Psychosocial interventions for preventing and treating depression in dialysis patients 2019 · Cochrane Headline outcomes only
  SMD 0.51 [0.19, 0.83]
  4 studies · 230 participants
  Moderate

Surgery vs preoperative pharmacological therapy and surgery

The review found no eligible studies for this question.

• Surgical and non‐surgical interventions for primary and salvage treatment of growth hormone‐secreting pituitary… 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Radioembolisation plus sorafenib vs sorafenib monotherapy

The review found no eligible studies for this question.

• Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

IStent (or iStent inject) vs medical therapy

The review found no eligible studies for this question.

• Ab interno trabecular bypass surgery with iStent for open‐angle glaucoma 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rituximab (2 x 1000 mg) plus methotrexate vs methotrexate

Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).

• Rituximab for rheumatoid arthritis 2015 · Cochrane Headline outcomes only
  RR 2 [1.1, 3.4]
  4 studies · 1526 participants
  High

Summary of findings: insulin detemir vs NPH insulin

• (Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 870 participants
  Low

Physical activity vs usual care

• Physical activity interventions for disease‐related physical and mental health during and following treatment in… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 230 participants
  Moderate